$HIMS News

Barclays Maintains Overweight on Hims & Hers Health, Lowers Price Target to $35

Hims & Hers Rejects Privacy Allegations While Promising Expanded Patient Access

Hims & Hers: Buying The Margin Dip

Hims & Hers: Eucalyptus Deal Unlocks New Markets

Hims & Hers Health's Next Act: Making Its Own Drugs Again

HIMS Q2 Deep Dive: AI Strategy and International Expansion Shape Telehealth Outlook

Hims & Hers Health (HIMS) Stock Looks Cheap Even With Legal Risk

Hims & Hers: The Guidance Raise Doesn't Fix The Margin Problem

HIMS Stock Snaps 2-Day Climb: Analyst Says Record Subscriber Growth ‘Not Enough’ To Offset Margin Slide

Is Hims The Next Big Name In Peptides? Shares Topple Despite Sales Beat.

Will Hims & Hers’ Higher 2026 Revenue Guidance Amid Rising Losses Change HIMS’s Investment Narrative?

Hims & Hers stock trims losses following quarterly results

Hims & Hers Q2 revenue beat offset by wider-than-expected loss

Citigroup Maintains Neutral on Hims & Hers Health, Lowers Price Target to $33

Citi Says Hims & Hers’ Full-Year Outlook Indicates ‘Hefty’ Q4 Earnings Lift, Warns Of Execution Risks

Hims & Hers Health Sees Mixed Q2 as Gross Margin, FCF Weigh, Morgan Stanley Says

HIMS Q2 Earnings Call Focuses on AI and Global Expansion

Deutsche Bank Maintains Hold on Hims & Hers Health, Raises Price Target to $26

Hims & Hers' Revenue Growth Comes at a Cost

B of A Securities Maintains Neutral on Hims & Hers Health, Raises Price Target to $32